Clinical Outcomes in Fibrolamellar Hepatocellular Carcinoma Treated with Immune Checkpoint Inhibitors

SIMPLE SUMMARY: Fibrolamellar hepatocellular carcinoma (FLC) is a rare form of liver cancer that affects children and young adults. Although immune checkpoint inhibitors (ICIs) including anti-PD-1 and anti-CTLA-4 are becoming standard of care in various cancers, including other forms of liver cancer...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Krista Y., Popovic, Aleksandra, Hsiehchen, David, Baretti, Marina, Griffith, Paige, Bista, Ranjan, Baghdadi, Azarakhsh, Kamel, Ihab R., Simon, Sanford M., Migler, Rachael D., Yarchoan, Mark
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9655068/
https://www.ncbi.nlm.nih.gov/pubmed/36358766
http://dx.doi.org/10.3390/cancers14215347

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9655068/
https://www.ncbi.nlm.nih.gov/pubmed/36358766
http://dx.doi.org/10.3390/cancers14215347

Ejemplares similares